Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Market Cap & Net Worth: Aerovate Therapeutics Inc (AVTE)
Aerovate Therapeutics Inc (NASDAQ:AVTE) has a market capitalization of $77.68 Million ($77.68 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #36249 globally and #11791 in its home market, demonstrating a -2.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aerovate Therapeutics Inc's stock price $2.68 by its total outstanding shares 28985000 (28.98 Million).
Aerovate Therapeutics Inc Market Cap History: 2021 to 2025
Aerovate Therapeutics Inc's market capitalization history from 2021 to 2025. Data shows change from $341.73 Million to $77.68 Million (-42.84% CAGR).
Index Memberships
Aerovate Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #899 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2811 of 3165 |
Weight: Aerovate Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aerovate Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aerovate Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AVTE by Market Capitalization
Companies near Aerovate Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Aerovate Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aerovate Therapeutics Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Aerovate Therapeutics Inc's market cap moved from $341.73 Million to $ 77.68 Million, with a yearly change of -42.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $77.68 Million | +1.13% |
| 2024 | $76.81 Million | -88.29% |
| 2023 | $655.93 Million | -22.76% |
| 2022 | $849.26 Million | +148.52% |
| 2021 | $341.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Aerovate Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $77.68 Million USD |
| MoneyControl | $77.68 Million USD |
| MarketWatch | $77.68 Million USD |
| marketcap.company | $77.68 Million USD |
| Reuters | $77.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.